{"id":"NCT02764801","sponsor":"Sidney Kimmel Cancer Center at Thomas Jefferson University","briefTitle":"Contrast-enhanced Ultrasound Evaluation of Chemoembolization","officialTitle":"2D and 4D Contrast-enhanced Ultrasound Evaluation of Hepatocellular Carcinoma Chemoembolization","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-04","primaryCompletion":"2021-12","completion":"2023-02-01","firstPosted":"2016-05-06","resultsPosted":"2023-09-21","lastUpdate":"2025-05-06"},"enrollment":131,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"DIAGNOSTIC"},"conditions":["Hepatocellular Carcinoma","Chemoembolization, Therapeutic"],"interventions":[{"type":"DRUG","name":"Ultrasound contrast agent (Contrast-enhanced ultrasound)","otherNames":["Definity (Lantheus Medical Imaging)","Microbubble contrast agent"]},{"type":"DEVICE","name":"Logiq E9 Scanner (Contrast-enhanced ultrasound)","otherNames":["Ultrasound Scanner"]}],"arms":[{"label":"Contrast ultrasound arm","type":"EXPERIMENTAL"}],"summary":"The primary objective of this trial is to evaluate the sensitivity and specificity of 2D and 4D contrast enhanced ultrasound for monitoring transarterial chemoembolization (TACE) response 1-2 weeks and 1 month post treatment as an alternative to contrast-enhanced magnetic resonance (MRI) or computed tomography (CT) imaging","primaryOutcome":{"measure":"Percentage of Patients Correctly Identified as Requiring Tumor Re-treatment Two Weeks After Initial Chemoembolization","timeFrame":"Percentage of patients correctly identified as requiring re-treatment will be identified 1-2 weeks after the subject's chemoembolization procedure","effectByArm":[{"arm":"Contrast Ultrasound Arm","deltaMin":94,"sd":null}],"pValues":[]},"eligibility":{"minAge":"21 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":10},"locations":{"siteCount":3,"countries":["United States"]},"refs":{"pmids":["25911704","17296705","37847138"],"seeAlso":["https://www.ncbi.nlm.nih.gov/pubmed/25911704","https://www.ncbi.nlm.nih.gov/pubmed/17296705"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":103},"commonTop":["post-embolization syndrome","nausea/vomiting","IV infiltration"]}}